Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970583 | 0.92 | GPR119 (0.47) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5970718 | 0.92 | GPR119 (0.47) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5971171 | 0.90 | GPR119 (0.49) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5864914 | 0.90 | GPR119 (0.51) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5970562 | 0.89 | GPR119 (0.42) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5971205 | 0.88 | GPR119 (0.48) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5864930 | 0.88 | GPR119 (0.48) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5970909 | 0.88 | GPR119 (0.59) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5970402 | 0.88 | PDE4B (0.57) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5970676 | 0.87 | GPR119 (0.43) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | GPR119 1622/4885PDE4D 3926/4885PDE4B 3861/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3838/4885PDE4D 4062/4885PDE4B 3983/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3852/4885PDE4D 4105/4885PDE4B 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.